Understanding cardiac safety early is critical in drug development. In their latest poster, Jazz Pharmaceuticals, explain how they utilised Metrion’s clinically translatable cardiotoxicity assay to do exactly that. The poster describes data from Metrion’s high-throughput VOLTA assay with human iPSC-derived cardiomyocytes, combined with patch-clamp IC50 data from cells expressing hERG, NaV1.5 and CaV1.2. Once again, Metrion’s specialist cardiotox scientists improved the ability to predict QTc and QRS changes and identify cardiovascular liabilities much earlier in the discovery process.
Complete the form to download the poster.
Optical voltage imaging of human iPSC-derived cardiomyocytes was used to assess electrophysiological effects of compounds beyond hERG inhibition. Action potential waveform analysis revealed compound-specific and concentration-dependent changes, enabling mechanistic differentiation of multichannel activity and demonstrating a human-relevant approach for translational cardiac safety assessment.
The presence of sensory neuron markers, excitability properties consistent with sensory neurons, and evidence of nociceptor ion channels (using both RNASeq and electrophysiology) provides strong evidence that iCell Sensory Neurons have a robust sensory neuron phenotype suitable for supporting pain discovery programs.